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ABSTRACT 
Efficient drug delivery is dependent on the drug substance dissolving in the body fluids, being 
released from dosage forms and transported to the site of action. A fundamental understanding of 
the interplay between the physicochemical properties of the active compound and pharmaceutical 
excipients defining formulation behavior after exposure to the aqueous environments and 
pharmaceutical performance is critical in pharmaceutical development, manufacturing and quality 
control of drugs. UV imaging has been explored as a tool for qualitative and quantitative 
characterization of drug dissolution and release with the characteristic feature of providing real-time 
visualization of the solution phase drug transport in the vicinity of the formulation. Events 
occurring during drug dissolution and release, such as polymer swelling, drug 
precipitation/recrystallization, or solvent-mediated phase transitions related to the structural 
properties of the drug substance or formulation can be monitored and characterized by other 
analytical techniques like Raman spectroscopy. UV imaging is non-intrusive and simple-to-operate, 
which holds potential for providing a mechanistic foundation for formulation development. This 
review aims to cover applications of UV imaging in the early and late phase pharmaceutical 
development with a special focus on the relation between structural properties and performance. 
Potential areas of future advancement and application are also discussed. 
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ASD: Amorphous solid dispersion  
API: Active pharmaceutical ingredient  
BCS: Biopharmaceutics classification system 
CARS: Coherent anti-Stokes Raman scattering  
CBZ: Carbamazepine  
CMOS: Complementary metal oxide semiconductor  
DVS: Dynamic vapour sorption  
FaSSIF: Fasted state simulated intestinal fluid  
FTIR: Fourier transform infrared 
HPMC: Hydroxypropyl methylcellulose  
HP55: Hydroxypropyl methylcellulose phthalate  
MRI: Magnetic resonance imaging 
NIR: Near-infrared  
PLLA: Poly-L-lactic acid  
PC: Phosphatidylcholine 
NIC: nicotinamide 
SLS: Sodium lauryl sulfate  
SEM: Scanning electron microscopy 
UV: Ultraviolet 
Vis: Visible  
XRPD: X-ray powder diffraction  
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INTRODUCTION 
In vitro dissolution and release testing is a key activity in the pharmaceutical industry throughout 
the various phases of drug development. For example, the dissolution behavior of candidate 
molecules is assessed in early phase drug development as part of solid form selection; dissolution 
testing is used to guide dosage form development, in vitro – in vivo correlations and assessment of 
batch-to-batch quality [1–10]. The compendial dissolution testing methods have been criticized for 
variability and lack of biorelevance but remain essential tools for asserting performance and quality 
of drug products [4–6]. The compendial methods require large volumes of dissolution medium and 
sample which could not be suitablein early phase drug development due to only limited quantities 
of drug substance available. To this end, miniaturized or micro-dissolution apparatuses have been 
developed to overcome this chanllege and might potentially become a useful tool in pharmaceutical 
industry for drug candidate screening [7–9]. A number of the commonly employed dissolution and 
release testing methods rely on bulk solution measurements for drug quantification whereby 
dissolution events such as polymer swelling, drug precipitation, or solvent-mediated solid form 
transformation might not be detected [11–16]. Hence, platforms capable of providing real-time 
mechanistic information related to drug dissolution and release processes are desirable for an in-
depth understanding of these complex events.  
Imaging techniques providing spatially, and temporally resolved information on drug delivery 
systems are increasingly used in formulation design and development. These techniques include 
Raman spectroscopic methods [17–19], magnetic resonance imaging (MRI) [20–24], Fourier 
transform infrared (FTIR) spectroscopic imaging [25–27], near-infrared (NIR) spectroscopy and 
imaging [28,29], coherent anti-Stokes Raman scattering (CARS) [30,31] and UV imaging [32]. 
Information related to for example, water penetration, polymer swelling and dissolving, gel layer 
formation, drug concentration mapping inside and outside the formulation can be gained through 
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those versatile imaging platforms, e.g., [10,20,25,28,29,32,33]. However, for the purpose of 
dissolution and release testing, some of the imaging techniques are not fully commercially 
developedor well-established. , [10]. Ultraviolet-visible (UV-Vis) spectrophotometry has been used 
for decades for quantification due to the fact that most active pharmaceutical ingredients contain 
chromophores that absorb light in the UV or visible range [34]. UV imaging was introduced for 
drug release testing in 2010 [35] and is still a relatively new technology in formulation research. 
The creation of real-time images of API transport in or in the close proximity of the solid or the 
formulation subject to investigation have spurred interest in various areas from the determination of 
intrinsic dissolution rates to characterization of the in vitro performance of drug delivery systems 
such as studies on drug release kinetics or polymer swelling behavior. Relative to other imaging 
techniques, the non-intrusive measurements by UV-Vis imaging of the solution phase provide a 
complementary and comparatively simple platform for in vitro drug dissolution and release studies. 
The aim of this review is to discuss and assess the potential use of UV-Vis imaging in relation to 
formulation development. The UV imaging instrumentation and associated advantages and 
limitations have been covered in detail previously [32]. Thus, the current review aims to cover 
recent applications of UV-Vis imaging in the early and late phase drug development. Particular 
focus will be directed to the cases where UV imaging has been found useful for elucidating the 
interplay between structure and drug release.  
 
UV IMAGING INSTRUMENTATION 
UV imaging utilizes the native characteristic UV absorbance to create spatially and temporally 
resolved analyte concentration maps within a transparent material. The commercially available 
Sirius SDI (surface dissolution imaging) UV imaging system utilizes a pulsed Xe lamp as the light 
source, incorporates a band pass filter for wavelength selection, a fibre optic cable for presenting 
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the light to sample quartz cell, a lens for collimating the light and a CMOS (complementary metal 
oxide semiconductor) camera chip measuring the light intensity. The nominal imaging area of the 
Sirius SDI is 7 × 9 mm2 composed of 1024 × 1280 pixels each having the size of 7 × 7 µm2. The 
CMOS chip is only active in the visible wavelength range and a phosphorous coating in front of the 
chip converts the UV light into the visible range prior to detection [36]. The instrument design 
allows the use of only one wavelength at a time. For a detailed treatment of the performance 
characteristics of the SDI UV imaging instrument (and the related D100 unit), readers are referred 
to [36]. The UV imaging, or rather UV-Vis, imaging systems were tested in the wavelength interval 
200 to 650 nm. Due to the special configuration of light source, phosphorous conversion and 
CMOS chip, the SDI system appears to have a “blind” wavelength range from 300 to 350 nm where 
it is difficult or impossible to obtain good measurements due to lack of detector response. The 
resolution of the instrument was found to be in the range of ~50 to 200 µm depending on 
configuration and sample alignment [36]. This should be kept in mind when considering work with 
nano- and micro-particulates. Typically the light source and camera unit is attached to a syringe 
pump, temperature control unit and a low-volume flow-through quartz cell as shown schematically 
in Fig. 1. However, the design of the camera housing is compatible with various types of sample 
holders and quartz cells. Schematic representations of quartz cells applied for dissolution and 
release testing are shown in Fig. 2.  
 
UV IMAGING IN EARLY DRUG DEVELOPMENT 
Preformulation studies are an essential component in drug development to gain fundamental 
knowledge about the physicochemical properties of drug candidates in order to guide the 
development of an optimal pharmaceutical formulation. In the past few decades, an increasing 
number of new potential drug molecules which exhibite reasonable membrane permeability but 
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poor aqueous solubility have been discovered [4,5,37,38]. Hence, dissolution will often be the rate-
limiting step for in vivo drug absorption. Solid-form screening and selection aiming to identify the 
optimal solid form of the drug candidate as early as possible is an additional important part of the 
preformulation activities. The different solid forms of an API, potential solvent-mediated phase 
transformations, the presence of ions, surfactants or biorelevant components in the dissolution 
medium might significantly affect dissolution behaviour, which necessitates an in-depth 
understanding. UV imaging has been found useful in this area. An initial report [39] applied UV 
imaging with the assistance of Raman spectroscopy to assess the dissolution and identify the solid 
forms before and after dissolution of amlodipine free base, amlodipine besylate dihydrate and 
amorphous amlodipine besylate using the flow-through dissolution setup shown in Fig. 1. UV 
imaging possessed the discriminatory power to rank the three solid forms in terms of dissolution 
rate. Raman spectroscopy confirmed solid from changes inferred from the dissolution rate versus 
time profiles [39]. In a similar type of study, UV imaging was successfully employed to determine 
the dissolution properties of a range of compounds and solid forms, namely: theophylline (BSC I, 
anhydrate and monohydrate), indomethacin (BCS II, alpha and gamma form) and ibuprofen (BCS II, 
free acid and sodium salt), which, according to the authors, had proved difficult using conventional 
dissolution testing [40]. For example, the conversion of anhydrous theophylline to monohydrous 
theophylline in aqueous environments consititutes the main challenge for dissolution studies of 
theophylline anhydrate. However, due to fast analysis time and different hydrodynamic condition in 
UV imaging flow-through setup, this solid from transformation was not observed during the 
experiments and UV imaging demonstrated high discriminatory power [40].    Pharmaceutical co-
crystals have emerged as an approach for improving solubility and bioavailability of poorly soluble 
drugs [41–44]. Li and coworkers investigated the dissolution and transformation behavior of 
carbamazepine–nicotinamide (CBZ–NIC) cocrystals [45] as well as the effect of using surfactant-
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containing dissolution media on CBZ–NIC solubility and dissolution behavior using UV imaging, 
Raman spectroscopy and SEM [46]. The dissolution rate of CBZ–NIC cocrystals was higher within 
the first 3 h as compared to the carbamazepine form I and III as well as the dihydrate [45].  Off-line 
Raman spectroscopy revealed that CBZ–NIC cocrystal, carbamazepine I, carbamazepine III, and 
physical mixture transformed into the stable carbamazepine dihydrate during dissolution [45]. In the 
following study, the surfactants sodium lauryl sulfate (SLS) and Tween 80 had an interesting effect 
on the dissolution behavior of the CBZ–NIC cocrystal [46]. SLS and Tween 80 had little influence 
on the solubility of the cocrystal, but they had opposite effects on the intrinsic dissolution rate of the 
CBZ–NIC cocrystal. SLS increased the intrinsic dissolution rate of the CBZ–NIC cocrystal whereas 
Tween 80 apparently decreased its intrinsic dissolution rate probably related to the differences in 
their molecular structure and solubilisation mechanism [46]. For the CBZ–NIC cocrystal it was 
possible to find at suitable detection wavelength, however, multicomponent systems may pose a 
challenge using current UV imaging instrumentation where only one wavelength is available at a 
time. 
   Application of physiologically relevant dissolution media in dissolution testing is important in 
order to simulate the in vivo situation as closely as possible and, also, UV imaging have been 
conducted using bio-relevant media [47–49]. Gordon et al. found that the dissolution behavior of 
furosemide was not significantly influenced by applying the fasted state simulated intestinal fluid as 
compared to pure buffer solution [47]. For a number of samples, pronounced irregular upward shifts 
of the contour lines in UV absorbance maps were observed. Such observations may indicate 
dissolution followed by precipitation associated with solid form transformation or swelling of the 
solid material. In the particular case, in situ Raman spectroscopy as well as XRPD analysis 
demonstrated that the observed swelling at the compact surface was not associated with a solid form 
transformation [47]. Such an occurrence remains an observation of interest. Subsequently, the 
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dissolution behavior of amorphous furosemide sodium salt and amorphous furosemide (acidic 
neutral species) in simulated bio-relevant intestinal medium was studied in comparison with the 
corresponding crystalline forms [48]. The two furosemide sodium salt forms (amorphous or 
crystalline) were found to have higher dissolution rates than the two acidic forms. The conversion 
of the amorphous form to crystalline form was fast in both cases as detected by Raman 
spectroscopy. Niederquell and Kuentz applied UV imaging-based dissolution testing to the poorly 
water soluble acids celecoxib, ketoprofen, naproxen, and sulfathiazole in fasted state simulated 
intestinal fluid [49]. For all four compounds, a high and variable initial dissolution rate was 
followed by decreasing dissolution rates with time approaching a pseudo-equilibrium state. This 
time dependent dissolution behaviour, which may be found in other UV imaging studies as well, 
was related to sample heterogeneiety and discussed in terms of fractal-like dissolution behavior [49]. 
This important study emphasizes the importance of studying heterogeneity-related effects in small 
scale in vitro dissolution testing. 
    Identification of solid form transformations in relation to the in vitro dissolution studies has 
mainly been achieved using off-line Raman spectroscopy or XRPD, normally performed before and 
after dissolution measurements. Alternatively, as reported by Nielsen et al. [48], in situ Raman 
spectroscopy can be performed using a flow-through cell similar to that used with the UV imaging 
system making essentially parallel studies. However, in cases where the API availability is limited, 
parallel measurements would not be feasible and off-line studies may be unlikely to capture the 
transformation kinetics due to changes in hydrodynamic conditions. Østergaard et al. developed an 
integrated dissolution setup combining UV imaging with a Raman spectroscopy probe [50]. The 
dissolution of sodium naproxenate in dilute hydrochloric acid and theophylline anhydrate in water 
constituted the model systems applied for demonstrating the suitability of the approach. Conversion 
of theophylline anhydrate into the monohydrate was observed as expected from literature. More 
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interestingly, two intermediate forms were detected by Raman spectroscopy during the 
transformation of sodium naproxenate to the neutral naproxen form upon dissolution in 0.1 M HCl 
[50]. Such intermediate forms might otherwise be overlooked through traditional dissolution 
method or an offline Raman spectroscopic characterization. 
   The UV imaging-based dissolution studies performed using the flow-through setup highlight the 
significance of real-time information provided by UV imaging as well as the importance of 
combining with suitable solid-state characterization techniques. Key features of the so-called 
surface dissolution imaging setup include low sample requirements (3 to 10 mg), potential for rapid 
dissolution tests, testing periods from 10 min to several hours, possibility to apply bio-relevant 
dissolution media (this may be wavelength specific), and information related to the behavior of the 
solid material upon exposure to the dissolution medium. The imaging offers important qualitative 
information regarding the dissolution process in addition to the typical quantitative data. In the 
hands of the authors, flow-through dissolution testing using UV imaging tend to be less 
repeatable/robust as compared to what is expected from traditional dissolution tests, this may be 
related to the small scale and sample preparation issues. As an example, Boetker et al. employed 
finite element simulation to characterize the hydrodynamics of the UV imaging flow cell [51]. 
Good agreement was found between the dissolution rates determined from the collected effluents 
and the developed numerical model. However, deviations were observed upon comparison of the 
dissolution rates determined from the UV images using the instrument software to those obtained 
from the finite element simulations and the effluents. Suggested causes for the discrepancy related 
to the finite size of the pixels, that the incident light had an angle different from 0o, and formation of 
the density gradients around the compact surface [51]. Since the time of the study, a lens for 
improving collimation of the incident light has been incorporated. In any case, further 
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characterization of the UV imaging system may be needed to clarify the role of these factors on 
dissolution rate determination. 
    Of particular interest in a preformulation setting, Lu and Li recently reported on a UV imaging 
method for simultaneous determination of drug solubility and diffusion coefficient by fitting 
imaging data to a numerical model derived from Fick’s second law of diffusion [52]. The 
solubilities calculated for carbamazepine and ibuprofen were in good agreement with literature data. 
Experiments were executed within 5 min, allowing estimation of the apparent solubility of a 
thermodynamically unstable compunds, e.g., carbamazepine form II [52].  
   Imaging the dissolution of individual crystals may be of interest since it might provide 
fundamental knowledge regarding the dissolution mechanism of a crystalline API. A first attempt of 
applying UV imaging in this area investigated the dissolution of a single crystal of lidocaine in 
stagnant buffer solution [53]. The absorbance maps clearly visualized the influence of natural 
convection due to density gradients on the dissolution of lidocaine. It is tempting to speculate that 
such measurements can be further developed into a setup where face-specific dissolution can be 
investigated. 
    Assessment of micro-environmental pH changes during dissolution may be of relevance for 
ionizable drug substances as well as their formulations since the local pH influences dissolution and  
release performance [54]. A proof of concept study mapped the local pH change in relation to the 
dissolution of sodium naproxenate in 0.01 M and 0.10 M hydrochloric acid using a Vis imaging-
based approach and a pH indicating dye thymol blue [55]. The approach should be termed Vis 
imaging rather than UV imaging since the local pH was assessed from the change in absorbance at 
550 nm. Results showed the dissolution of sodium naproxenate could cause significant temporary 
pH changes in the dissolution medium in the vicinity of the solid salt. Parallel UV imaging studies 
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monitored the dissolution of sodium naproxenate under the conditions where the salt was eventually 
neutralized and precipitated as the acidic species naproxen.  
    To sum up, UV imaging in combination with solid state characterization techniques such as 
Raman spectroscopy seems to offer an interesting experimental setup in preformulation and early 
phase development facilitating basic dissolution behavior to be monitored. A caveat may be that 
studies have been performed using well-known model APIs. Cases where UV imaging data have 
been succesfull (or the opposite) in progressing development candidates are less likely to become 
public available. 
 
UV IMAGING IN FORMULATION DEVELOPMENT 
   Much effort is put into delineating the interdependence between dosage form structure and release 
kinetics. Imaging techniques can be used to visualize, for instance, how drug-polymer interactions 
affect release upon exposure to aqueous environment. In general, as compared to other chemical 
imaging techniques, UV images contain little structural information image. .Still, as will be 
discussed in the following, UV imaging is likely to play a role in the characterization of drug-
excipient interactions and formulation development. This section covers applications of UV 
imaging in this area divided according to route of administration.  
 
Oral Route of Administration 
  Hydrophilic polymers are widely used to control the release rate of API in tablets for oral 
administration. Visualization of the swelling process of hydroxypropyl methylcellulose (HPMC) in 
an aqueous solution has been achieved by MRI [22,56,57], FTIR imaging [58–61] or near infrared 
chemical imaging [29]. Pajander et al. investigated HPMC swelling using UV imaging under 
stagnant conditions as well as in the presence of flow [62]. Compacts of two viscosity grades of 
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HPMC, 15 cP and 50 cP, were prepared and subjected to real-time visualization of the polymer 
behavior at 214 nm. It is widely accepted that several events take place sequentially upon HPMC 
contact with aqueous solution [63,64]. The polymer entanglement and swelling leading to the 
formation of a gel layer was apparent by UV imaging. Distinct features such as the diffusion layer, 
erosion front and gel point was inferred from the images. The swelling behavior of the 15 cP and 50 
cP HPMC qualities was slightly different as characterized by UV imaging, the higher viscosity 
grade HPMC swelled faster and formed a thicker gel layer, being less susceptible to erosion in the 
presence of flow [62].  
  Amorphous solid dispersions (ASDs) constitute a potential avenue for improving oral 
bioavailability. Amorphous solid dispersions involve amorphization of a crystalline API by 
dispersion in an amorphous hydrophilic polymer with a high glass transition temperature (Tg) [65–
67]. The molecular mobility of the API is significantly reduced and stabilized against crystallization 
while embedded in the polymer matrix [68]. A key hurdle associated with the development of ASDs 
may be a limited understanding of the relationship between physical structure, stability and 
pharmaceutical performance [66,68]. Nilotinib exhibited improved bioavailability in dogs when 
formulated with hydroxypropyl methylcellulose phthalate (HP55) and surfactants upon carbon-
dioxide-mediated processing [69]. Colombo et al. systemically studied the polymer matrix effects 
on dissolution and re-precipitation kinetics mediated by this ASD formulation  using simultaneous 
UV-imaging and Raman spectroscopy [70]. HP55, crystalline nilotinib, HP55-nilotinib ASDs with 
20% and 40% drug load and the corresponding physical mixture were investigated in a simulated 
gastrointestinal environment. The structural changes with respect to swelling and dissolution 
behavior of the polymer in an acidic environment (pH 2.2) as well as neutral solution (pH 6.4) were 
reflected as changes in matrix height (swelling) at the center of the compacts (Fig. 3). Results 
showed that different drug loads led to distinctively different formulation behaviour. A 20% drug 
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load suppressed the polymer swelling and seemingly formed a homogenous gel layer in acidic 
medium. After a change to near neutral pH, the dissolution of the polymer did not occur 
immediately as for pure HP55 compacts; instead, a slight increase in matrix height was observed 
which might suggest a re-organization of the gel structure induced by the pH change. High nilotinib 
load (40%) prevented matrix swelling even further at acidic pH and remained stable in neutral 
environment. With respect to dissolution, the 40% drug load formulation displayed a remarkable 
increased dissolution after change into the neutral pH as compared to the other samples. Those 
findings are of interest since utilizing HPMC with the absence of phthalate groups did not show 
drug-load dependent swelling and dissolution behavior. These results in combination with the data 
obtained from simultaneous Raman spectroscopy demonstrated that higher drug load formulation 
(40% nilotinib) efficiently prevented the recrystallization of nilotinib from the amorphous solid 
dispersion after being exposed to the pH 6.4 medium. The drug–polymer hydrogen-bonding, 
mediated by the phthalate groups was crucial in determining this effect. This study highlights the 
potential application of UV imaging in revealing the interplay of dosage form microstructure and 
dosage form performance.  
    Lipid-based drug delivery systems constitute a versatile approach for increasing the 
bioavailability of poorly soluble APIs [38,71]. Gautschi et al. studied drug release from drug–
phospholipid complexes by UV imaging [72]. Formulations were prepared using monoacyl or 
diacyl phosphatidylcholine (PC) as excipients and a series of poorly soluble compounds (BCS II 
and IV) to characterize the feasibility of forming drug-phospholipid dispersions at a 1:1 molar ratio. 
The ability to form solid dispersions with the phospholipids was related to API physical chemical 
parameters such as frontier orbital energy, enthalpy of fusion, and log P [72]. Dissolution studies 
using UV imaging showed a remarkable surface swelling of the solid dispersions over the compact 
surface due to phospholipid hydration. Monoacyl PC enhanced drug release rate, whereas diacyl PC 
15 
 
had only limited effect on the drug dissolution rates. Two factors were suggested to contribute to 
this observation, drug precipitation during hydration and the inability to form micelles in case of the 
diacyl PC as compared to mono-acyl PC [72]. 
   Gaunø et al. applied UV imaging to monitor the in vitro release behavior of single 5-
aminosalicylic acid extrudates with different thicknesses of ethyl cellulose coating applied and 
compared the results with traditional bulk release testing using the traditional paddle method [73]. 
The individual extrudates (~1 mm in length) were embedded in an agarose hydrogel matrix keeping 
the extrudate in position during the measurements. Both UV imaging and paddle dissolution 
method confirmed that the release of 5-aminosalicylic acid from the extrudates decreased with 
increasing film coating layer thickness [73]. UV imaging was also capable of visualizing coating 
defects inflicted on the extrudates [73]. As a proof of concept study, the extrudate was manually 
damaged at different area and 5-aminosalicylic acid was found released faster from the 
compromised area leading to the formation of an asymmetrical absorbance map around the 
extrudate in comparison with the symmetrical spherical absorbance maps formed around the 
undamaged extrudates [73]. UV imaging measurements might provide a rapid and simple platform 
for detection of film coating defects [73]. 
 
 Drug nano-crystals are investigated as an approach to increase the biavailability of poorly soluble 
drugs [74–76]. Indomethacin nano-crystals with different particle sizes in the range of 580–950 nm 
were prepared using poloxamer F68, poloxamer F127 and polysorbate 80 as stabilizers through a 
top-down wet milling technique [77]. The dissolution of indomethacin from compacts formed from 
compression of the nano-crystals was compared to the dissolution of unmilled indomethacin as well 
as the corresponding physical mixture using UV imaging and a traditional flow-through dissolution 
method. Initial UV and Vis imaging experiments revealed a significant increase in absorbance 
16 
 
during flow-through dissolution at 265 nm where indomethaxin absorbs light strongly as well as at 
550 nm where indomethacin has no absorbance. This observation was ascribed to the nanocrystals 
escaping the compact surface to the dissolution medium leading to the light scattering instead of 
absorbance due to molecularly dissolved indomethacin [77]. The dissociation of particles from the 
surface was suppressed using a hydrogel matrix. Under these conditions, the nano-crystal compacts 
exhibited a significantly higher dissolution rate as compared to unmilled indomethacin [77]. The 
indomethacin concentration in the immediate vicinity of the nano-crystal compact was almost five 
times the solubility which might be related to the supersaturation. Although, the solubility 
enhancing effects by poloxamer F68 or F127 may also contribute to the increased local 
indomethacin concentration [77].  
   Micro-fabricated devices have been proposed as novel oral delivery systems since the size and 
shape of the devices can be manipulated in order to maximize the contact area with absorptive 
tissue and improve bioavailability [78,79]. Nielsen et al. employed UV imaging as well as the μ-
Diss profiler to characterize the release of amorphous sodium salt of furosemide from microwells 
(240 µm inner diameter) fabricated with poly-L-lactic acid (PLLA) and coated with Eudragit® 
L100 [80]. Simulated gastric and intestinal media were utilized in the dissolution study to be as 
close as possible to the in vivo situation. Both UV imaging and the μ-Diss profiler revealed the 
same trend with an absence of drug release in the gastric medium and an immediate furosemide 
release from the assemblies of coated microwells subject to testing after switching to the simulated 
intestinal medium due to the pH change. In this particular study, the UV images were used in a 
qualitative manner to assess the Eudragit® coating protecting the drug from being released in an 
acidic environment. 
 
Parenteral Adminstration 
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   Most approved protein and peptide-based medicines are administered via the parenteral route 
(intramuscular, subcutaneous or intravenous injection) due to their susceptibility to enzymatic 
degradation and poor membrane passage [81–83]. However, currently there are no standardized 
regulatory approved in vitro release testing methods for parenterals [84,85]. In vitro platforms 
capable of predicting bio-performance of parenteral depots for administration into soft tissue are 
desirable in formulation development. UV imaging-based approaches incorporating a hydrogel 
matrix as soft tissue model has been proposed for characterization of such depot systems [86–92]. 
Model drug substances, with low and high molecular weight have been studied to assess the 
feasibility of this setup in in vitro drug release measurements. Ye et al. employed pluronic F127 as 
the hydrogel matrix and investigated the diffusion of piroxicam and human serum albumin in the 
gel matrix using a rectangular parallel piped quartz cell, half of which was filled the formulation, 
the other half with dissolution medium (see Fig. 2B and 2C) [86]. By fitting the experimental data 
to an equation derived from Fick’s second law, the apparent diffusion coefficients of piroxciam and 
human serum albumin in 20% (w/w) F127 were determined. Diffusion and partition of piroxicam 
from oil solution into hydrogel matrixes (agarose and pluronic F127-based) mimicking 
subcutaneous tissue were also investigated [87]. In a subsequent study, two piroxicam solutions 
(aqueous and oily) were injected into an agarose hydrogel matrix using the setup sketched in Fig. 
2D in order to more closely simulate subcutaneous administration [88]. Spatial concentration 
distributions of drug around the injection site were monitored in real-time. From the spatially and 
temporally resolved absorbance data, diffusion coefficients and distribution coefficients have been 
obtained using Fick’s second law [87,88]. Also in the context of subcutaneous administration, 
Jensen et al. investigated the diffusion of human insulin in an agarose gel matrix [90]. The self-
association properties of human insulin were reflected in the diffusional transport, essentially 
determining the hydrodynamic radii corresponding to the insulin monomer, dimer and hexamer 
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from the diffusion measurements conducted by UV imaging [90]. Changes in pH of the surrounding 
microenvironment during dissolution of amorphous insulin in agarose matrixes at pH 3.0, 5.4 and 
7.4 [91] were investigated using the pH indicator method previously introduced [55]. Local pH 
changes reflecting protonation and deprotonation of dissolved insulin molecules were proposed to 
explain anomalous insulin dissolution profiles. In the same context, using human insulin as a model 
protein, three different in vitro dissolution methods for assessing insulin release from lipid implants 
were evaluated including: i) agitated vials filled with bulk dissolution medium, ii) release in an 
agarose gel, insulin quantified in cored-out gel samples (as described in [93]) and iii) in an agarose 
gel as shown in Fig. 2E with insulin detection via UV imaging [92]. In accordance with 
expectations, insulin release from Sterotex implants with a drug load of 20% (w/w) was faster as 
compared to the release from implants with a drug load of 10% (w/w). However, interestingly 
implants with a high drug load of 20% displayed similar release profiles independent of the in vitro 
release methods used whereas the implants with a drug load of 10% exhibited a faster insulin 
release in an agitated buffer solution than in the stagnant agarose hydrogel matrixes [92]. Further 
studies are needed to unravel the interplay between release behavior and in vitro release testing 
conditions. This study highlights the importance of the in vitro testing conditions on drug release 
from parenteral depot systems and provides proof-of-concept to the use of UV imaging in the 
characterization of implants. It is also clear that future work could benefit significantly from access 
to instrumentation with a larger imaging area. 
    In our view the studies above suggest that hydrogel matrixes are worth pursuing in the search for 
suitable in vitro release testing methodologies for injectables. For liquid injectables a matrix acts to 
confine the preformulation or formulation. In combination with UV imaging, transpancy of the 
matrix is a fundamental requirement but much can be done in terms of altering the properties of the 
matrix as recently shown. Composite hydrogels containing agarose in combination with the 
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biorelevant polyelectrolytes chondroitin sulfate and hyaluronic acid was prepared and the diffusion 
of low molecular weight substances and two proteins was investigated by UV imaging [89]. 
Incorporation of the negatively charged polyelectrolytes into the hydrogels reduced the apparent 
diffusivities of the cationic model compounds as compared to the pure agarose gel. Inclusion of 
tissue components may be an approach to increase the biorelevance of the in vitro methods as well 
as to probe the importance of specific interactions for a given API or formulation. 
 
Other Routes of Administration 
   The release of nicotine from 2 mm in diameter samples of Nicorette® transdermal patches into 
phosphate buffer, pH 7.40, constituted the first application of UV imaging [35]. Using a flow-
through cell, the release of nicotine into a stagnant or a constant flow of phosphate buffer was 
monitored in real time. Visualization of the development of nicotine concentration gradients in the 
aqueous phase next to the sample patch as well as quantification of the nicotine release rate was 
achieved with UV imaging. The nicotine release rate determined by UV imaging was higher than 
that attained using the traditional paddle over disk method. This apparent discrepancy was ascribed 
to edge effects associated with the geometry and positioning of the samples in the flow cell [35]. 
   The antibiotic chloramphenicol was applied as a model drug in the preparation of in situ forming 
gels intended for ophthalmic administration [94]. The effect of poloxamer concentration, addition of 
thickener, simulated tear fluid and pH on the gelation temperature and release rate of 
chloramphenicol from in situ forming gels was evaluated using a UV imaging based flow-through 
setup.  UV imaging was found suitable for characterization of ophthalmic in situ forming gels being 
capable of discriminating chloramphenicol release behavior from different formulation 
compositions [94]. 
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CONCLUSION 
With the appearance of new challenging drug molecules, there is a push to develop novel, flexible 
dissolution testing methods in order to reduce development cost and use less animal experiments. 
The conventional dissolution testing approaches exhibit a various drawbacks limiting the ability to 
predict in vivo behavior. Being able to non-invasively image the dissolution process, UV imaging in 
combination with other spectroscopic techniques such as Raman spectroscopy allows the micro-
environment and structure of dosage forms to be characterized with respect to monitoring local pH 
changes, polymer swelling, drug precipitation or re-crystallizion, solvent-mediated phase transition, 
peptide self-association and electrostatic interactions. In comparison to other imaging techniques, 
like Raman spectroscopy imaging, MRI or Fourier transform infrared (FTIR) imaging, the 
utilization of UV imaging to study pharmaceutical performances in vitro is still at an ealy stage. The 
application of UV imaging over the past five years demonstrated its potential use in relation to a 
range of different drug substances and delivery systems. Considering continuing improvements in 
hardware, implementation of quality-by-design concepts and benefits of real-time release 
information, it is anticipated that UV imaging may increasingly used in formulation development. 
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Legends to Figures 
Fig. 1 (A) Schematic representation of the commercially available Sirius SDI with ActipixTM 
technology UV dissolution imaging showing the key components of the instrument. (B) Schematic 
representation of the side-view of the UV imaging experimental setup. 
 
Fig. 2 Schematic of the sample cells applied in UV imaging systems. Pink represents the 
formulation or drug substance and white represents the release/dissolution medium. (A) Flow-
through cell used for studying dissolution (7.5 mm × 3.0 mm × 63.0 mm (H × W × L)). (B) 
Rectangular cell with one side filled with formulation, the other side with dissolution media while 
stirring (7.5 mm × 3.0 mm × 63.0 mm (H × W × L)). (C) Rectangular cell with one side filled with 
formulation, the other side with dissolution media at stagnant condition for studying diffusion or 
partitioning in a gel matrix (8.0 mm × 1.0 mm × 38 mm (H × W × L)). (D) Formulation injected 
into dissolution media through syringe (7.0 mm × 3.0 mm × 63 mm (H × W × L)). (E) Circular cell 
for studying drug release in hydrogel matrixes (15 mm (id) × 5 mm). 
 
Fig. 3 (A) Representative images of HP55 compacts showing swelling in citrate buffer, pH 2.2 and 
(B) dissolution after pH change to pH 6.4. Adapted with permission from Elsevier [70]. 
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